Advancing Biologics Development With Next-Generation Cell Line Development

By Woo Chi, Ph.D., Director, Cell Line Development, Yingji Jin, Ph.D., Associate Director, Cell Line Development, and Jaeeun Kim, Scientist, Cell Line Development

As the biologics market grows in complexity, cell line development (CLD) platforms must deliver increased speed, consistency, and product quality. Discover an advanced, integrated CLD platform that addresses these challenges through three key innovations:

• Transposase Technology: This system enables semi-targeted gene integration, minimizing positional effects and clone-to-clone variability, which can shorten development timelines for complex molecules to as little as 2 to 3.5 months. It has demonstrated up to a seven-fold increase in product concentration compared to traditional methods.
• S-AfuCHO™ Cell Line: An engineered line that achieves afucosylation by knocking out the FUT8 gene, significantly enhancing antibody-dependent cellular cytotoxicity (ADCC)—a critical quality attribute for oncology and immune-therapy programs.
• High-Throughput Lectin Assay: A rapid screening tool for early-stage glycosylation profiling, which can analyze 96 samples in 20 minutes using small volumes of unpurified fluid. This enables early control over critical quality attributes like sialylation and fucosylation, reducing downstream risk.

This integrated approach helps streamline early development and achieve clinical and commercial success for diverse therapeutic modalities. Explore how these next-generation tools drive higher yield and better product quality.